• Contact
  • Join
  • Log In
  • Profile
Canadian Centre for Applied Research in Cancer Control
  • Home
  • About
    • Our Team
    • Funding & Partners
    • FAQ
    • Contact Us
  • Research Areas
    • Research Projects
      • CanREValue Home
    • Health Technology Assessment
    • Health Systems, Services, and Policy
    • Societal Values and Public Engagement
    • Survivorship
    • Knowledge Translation
  • News
    • News
    • Funding
    • Jobs/Opportunities
  • Events
    • ARCC Conferences
      • ARCC Conference 2023 – #ARCC2023
      • ARCC Conference 2022 – #ARCC2022
      • ARCC Conference 2021 – #ARCC2021
      • ARCC Conference 2020
      • ARCC Conference 2019
        • Conference Presentations 2019
      • ARCC Conference 2018
        • Conference Presentations 2018
      • ARCC Conference 2017
        • Conference Presentations 2017
      • ARCC Conference 2016
        • Conference Presentations 2016
      • ARCC Conference 2015
        • Conference Presentations 2015
      • ARCC Conference 2014
        • Conference Presentations 2014
      • ARCC Conference 2013
        • Conference Presentations 2013
      • ARCC Conference 2012
        • Conference Presentations 2012
  • ARCC Network
    • Membership List
    • Capacity Building
    • Submission
    • Resources
      • Other Presentations
      • Conference Presentations
        • 2019 Conference Presentations
        • 2018 Conference Presentations
        • 2017 Conference Presentations
        • 2016 Conference Presentations
        • 2015 Conference Presentations
        • 2014 Conference Presentations
        • 2013 Conference Presentations
        • 2012 Conference Presentations
    • Links
  • Search
  • Menu
  • CanREValue Home
  • About Us
    • Our Team
  • Working Groups
    • Planning and Drug Selection Working Group
    • Reassessment & Uptake Working Group
    • Methods Working Group
    • Data Working Group
    • Engagement Working Group
  • Knowledge Translation
  • Resources

About Us

Drug costs represent a rapidly growing expense for health care systems. In cancer care, the emergence of new treatments has become a regular occurrence and easily outpaces budget growth. As a result, provincial funders must use evidence to prioritize and fund selected drugs from the pipeline of new drugs awaiting funding. Our team believes that the prioritization process should not only consider the evidence for the drugs in the pipeline when allocating resources, but also for drugs that are already being funded. Decisions to fund these drugs would have been made based on controlled clinical trials, where the population or environment may not reflect practice in the “real world”.

Our goal is to develop and test a framework for the generation and use of real world evidence (RWE) of cancer drugs to enable (i) reassessment of cancer drugs by recommendation-makers; and (ii) refinement of funding decisions or renegotiations/disinvestment by decision-makers/payers across Canada.

Our project has 4 objectives:

1. To develop an understanding of the current state of RWE in health care;

2. To develop and refine a framework for the generation and use of RWE dedicated to (i) policy/process and (ii) methodological applications of RWE;

3. To conduct multi-province RWE evaluations using the framework developed in Objective 2; and

4. To employ knowledge translation strategies to establish and integrate a working RWE framework into sustainable practice of participating provinces and on a national level. Our team will assemble a national panel of clinical, methodological, and policy experts to create adoptable RWE frameworks for cancer drug funding decisions. The RWE framework will not only support evidence-based policy reform, price renegotiations, and reallocation of funding from low- to high-value settings, but will also drive accountability and sustainability of the cancer system in an innovative way that can be replicated by all provinces and by other areas of health care.

Questions? Email us at CanREValue@cc-arcc.ca

 
CIHR logo

Recent Projects

  • The Canadian Centre for Applied Research in Cancer ControlPatient perspectives of Value Frameworks used to Guide Oncology Treatment DecisionsMay 1, 2021 - 12:27 pm
  • The Canadian Centre for Applied Research in Cancer ControlUnderstanding British Columbia cancer patients’ experiences with virtual health before and during the COVID-19 pandemicMay 1, 2021 - 11:53 am
  • The Canadian Centre for Applied Research in Cancer ControlBenchmarking End of Life Quality Indicators by Tumor Type & Describing models of palliative care across CanadaApril 1, 2021 - 8:56 am
  • The Canadian Centre for Applied Research in Cancer ControlEvaluation of the systemic cancer therapy volume-outcome association: a population-based study to inform the optimal provincial organization and delivery of systemic cancer therapyFebruary 1, 2021 - 12:20 pm

RECENT POSTS

  • CAHSPR is seeking the 2023 Article of the YearFebruary 1, 2023 - 7:41 am
  • CADTH Recognition Awards – Nominations Now Open!January 27, 2023 - 2:55 pm
  • Help establish research priorities for AYA Cancer in CanadaJanuary 27, 2023 - 7:36 am
  • BioCanRx – Summer Studentship – Call for ApplicationsJanuary 13, 2023 - 11:48 am

Login Status

Forgot?  Register
© Copyright 2021 - Canadian Centre for Applied Research in Cancer Control - Website by North Studio
Scroll to top
Translate »